Sagimet Biosciences (SGMT) Assets (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Assets of $107.8 million for Q1 2026, down 26.28% year-over-year from $146.2 million in Q1 2025, and down 7.49% quarter-over-quarter from $116.5 million in Q4 2025.
Sagimet Biosciences (SGMT) Assets (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Assets history runs 5 years deep, the most recent figure standing at $107.8 million for Q1 2026.
- In Q1 2026, Assets fell 26.28% year-over-year to $107.8 million; the TTM figure through Mar 2026 stood at $107.8 million (down 26.28% YoY), while the FY2025 annual figure was $116.5 million, down 27.32% from the prior year.
- Assets for Q1 2026 stood at $107.8 million, down from $116.5 million in the prior quarter.
- The five-year high for Assets was $194.5 million in Q1 2024, with the low at $21.5 million in Q2 2023.
- The 5-year median for Assets is $128.4 million (2025), against an average of $123.8 million.
- The sharpest annual moves came in 2024 and 2025: Assets surged 779.24% in 2024, then fell 27.32% in 2025.
- Sagimet Biosciences' Assets stood at $33.0 million in 2022, then soared by 192.81% to $96.7 million in 2023, then surged by 65.7% to $160.3 million in 2024, then dropped by 27.32% to $116.5 million in 2025, then fell by 7.49% to $107.8 million in 2026.
- Business Quant data shows SGMT's Assets at $107.8 million in Q1 2026, $116.5 million in Q4 2025, and $128.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | 263.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 263.43 Mn |
| Mar 31, 2026 | 107.76 Mn |
| Dec 31, 2025 | 116.48 Mn |
| Sep 30, 2025 | 128.40 Mn |
| Jun 30, 2025 | 137.41 Mn |
| Mar 31, 2025 | 146.17 Mn |
| Dec 31, 2024 | 160.26 Mn |
| Sep 30, 2024 | 174.78 Mn |
| Jun 30, 2024 | 189.02 Mn |
| Mar 31, 2024 | 194.53 Mn |
| Dec 31, 2023 | 96.72 Mn |
| Sep 30, 2023 | 102.93 Mn |
| Jun 30, 2023 | 21.50 Mn |
| Dec 31, 2022 | 33.03 Mn |